Article
Public, Environmental & Occupational Health
Xueyan Liang, Xiaoyu Chen, Huijuan Li, Xiaoxia Liu, Yan Li
Summary: This study evaluated the cost-effectiveness of the Chinese newly developed PD-L1 inhibitor sugemalimab plus chemotherapy (Sugema-Chemo) in China. The results showed that compared to chemotherapy alone, Sugema-Chemo increased QALY by 0.82 and life-years by 1.26, but with an average cost increase of $72,472. It was found that Sugema-Chemo might not be cost-effective for patients with metastatic NSCLC in China.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Oncology
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Summary: The independent risk factors for pemetrexed-induced nephrotoxicity in maintenance therapy were identified as non-evacuated third-space fluid, use of cisplatin during induction, and receiving more than 15 cycles of maintenance pemetrexed. To reduce the risk of nephrotoxicity, third-space fluid should be evacuated and carboplatin preferred over cisplatin whenever possible.
Article
Pharmacology & Pharmacy
Zhiwei Zheng, Huide Zhu, Ling Fang, Hongfu Cai
Summary: This study evaluated the cost-effectiveness of first-line additional sugemalimab in combination with chemotherapy vs. chemotherapy in the Chinese healthcare system using a three-state Markov model. The results showed that sugemalimab combination therapy is not economically advantageous for the first-line management of metastatic non-squamous NSCLC in China.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Neurosciences
Evelyn Dylda, Kuan Hong Wang
Summary: Prior actions can affect foraging choices in animals. Laboratory mice make rational foraging choices based on effort estimation, and prior actions to obtain rewards alter effort estimation and decision-making through motor skill learning.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2022)
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Article
Oncology
Evan J. Walker, Andrew H. Ko
Summary: Metastatic pancreatic cancer is conventionally treated with chemotherapy until disease progression or intolerable toxicity. Maintenance treatment aims to prolong progression-free and overall survival while maintaining quality of life by reducing chemotherapy dosage or introducing new drugs. This article summarizes existing data on maintenance treatments and discusses future directions in this field.
Article
Oncology
Jane Yanagawa, Gregory J. Riely
Summary: Significant advances have been made in the treatment of resectable non-small cell lung cancer (NSCLC) and metastatic NSCLC, including the use of neoadjuvant nivolumab + chemotherapy and adjuvant atezolizumab, as well as molecular testing for various gene mutations and targeted therapies.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Green & Sustainable Science & Technology
Vahakn Kabakian, Marcelle McManus
Summary: The viability of fuel-switching in the Lebanese cement sector has been discussed, and it has been found that shifting from heavy fuel oil and petcoke to natural gas is feasible, with scenario two being the only viable option.
ENVIRONMENT DEVELOPMENT AND SUSTAINABILITY
(2023)
Article
Oncology
Bin Zhou, Qiuyuan Li, Linlin Qin, Zhao Li, Kaiqi Jin, Jie Dai, Yuming Zhu, Yang Yang, Salma K. Jabbour, Alfredo Tartarone, Calvin S. H. Ng, Alfons Navarro, Cecilia Pompili, Gening Jiang
Summary: This study found that although almost half of octogenarians with small cell lung cancer did not receive active treatment, they may benefit from treatment. Chemotherapy combined with local therapy may be the best treatment option for advanced SCLC in octogenarians, while local therapy seems to play a more critical role in treating early-stage disease.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Taofeek K. Owonikoko, Keunchil Park, Ramaswamy Govindan, Neal Ready, Martin Reck, Solange Peters, Shaker R. Dakhil, Alejandro Navarro, Jeronimo Rodriguez-Cid, Michael Schenker, Jong-Seok Lee, Vanesa Gutierrez, Ivor Percent, Daniel Morgensztern, Carlos H. Barrios, Laurent Greillier, Sofia Baka, Miten Patel, Wen Hong Lin, Giovanni Selvaggi, Christine Baudelet, Jonathan Baden, Dimple Pandya, Parul Doshi, Hye Ryun Kim
Summary: Maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival (OS) for patients with extensive-disease small-cell lung cancer (ED-SCLC) who did not progress on first-line chemotherapy. However, there may be a benefit of nivolumab plus ipilimumab in patients with a tumor mutational burden of >= 13 mutations per megabase. The rates of grade 3-4 treatment-related adverse events were highest in the nivolumab plus ipilimumab group.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Construction & Building Technology
Yujie Lu, Peixian Li, Yih Perng Lee, Xiangnan Song
Summary: This study presents a framework for decision-making on energy retrofits for institutional buildings in a tropical climate, with a detailed case study as demonstration. The results suggest that occupants-oriented retrofit options perform better in energy retrofit, and it is recommended to adopt multiple retrofit measures together to enhance cost-effectiveness.
JOURNAL OF BUILDING ENGINEERING
(2021)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Chemistry, Analytical
Mark Schoot, Christiaan Kapper, Gijs van Kessel, Geert Postma, Lutgarde MC. Buydens, Jeroen J. Jansen
Summary: The long-term performance of spectroscopic calibration models is crucial for monitoring production processes. New variations over time may deteriorate prediction accuracy, requiring resources for model maintenance. A new method is proposed to quantify the effectiveness and cost of maintenance strategies based on historical data, aiming to improve prediction performance while being resource-efficient.
ANALYTICA CHIMICA ACTA
(2021)
Article
Critical Care Medicine
Shawn P. E. Nishi, Lisa M. Lowenstein, Tito R. Mendoza, Maria A. Lopez, Laura C. Crocker, Karen Sepucha, Jiangong Niu, Robert J. Volk
Summary: Among patients recently assessed for LCS, the quality of decision-making is highly variable, with patients valuing early cancer detection over concerns about harms. Patients were more likely to receive information on the benefits of LCS than on the risks, and one-third experienced some degree of decisional conflict. However, most patients felt they were adequately involved in the screening decision-making process.
Article
Oncology
Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang, Steven F. Powell, Ryan D. Gentzler, Renato G. Martins, James P. Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer
Summary: First-line pembrolizumab plus pemetrexed-carboplatin showed continued improved response and survival compared to chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Patricia J. Hollen, Richard J. Gralla, Ryan D. Gentzler, Richard D. Hall, Bethany Coyne, Haiying Cheng, Balazs Halmos, Jane Gildersleeve, Claudia Calderon, Ivora Hinton, Geoffrey Weiss, Jeffrey Crawford, Jane Cerise, Martin Lesser
Summary: This study aimed to explore whether patients with advanced non-small cell lung cancer (NSCLC) would feel regret after making treatment decisions. The research found that early risk assessment of patients can help intervene in feelings of regret, and deterioration in health status during early treatment increases the likelihood of regret.
Article
Oncology
Benjamin B. Morris, Nolan A. Wages, Patrick A. Grant, P. Todd Stukenberg, Ryan D. Gentzler, Richard D. Hall, Wallace L. Akerley, Thomas K. Varghese, Susanne M. Arnold, Terence M. Williams, Vincenzo Coppola, David R. Jones, David T. Auble, Marty W. Mayo
Summary: Evidence suggests that many patients with lung adenocarcinoma exhibit significant genome instability and overexpress the transcription factor MYBL2, which is associated with poor prognostic outcomes and potential disruption of DNA repair pathways.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Marino-Enriquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, Stephen F. Hodi, Jonathan D. Schoenfeld
Summary: This study demonstrated the feasibility and safety of adding low-dose fractionated radiation (LDFRT) and hypofractionated radiation (HFRT) to PD-L1/CTLA-4 blockade in patients with metastatic colorectal cancer. While the primary endpoint showed stable disease, biomarkers supported the impact of both LDFRT and HFRT on the immune microenvironment and immunogenicity.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylvie Vincent, Steven Zhang, Jianchang Lin, Veronica Bunn, Shu Jin, Shuanglian Li, Pasi A. Janne
Summary: Mobocertinib, an oral EGFR inhibitor targeting EGFR gene mutations in non-small cell lung cancer, demonstrated antitumor activity with manageable toxicity in patients with EGFRex20ins mutations in this study, supporting further development in this patient population.
Correction
Oncology
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Marino-Enriquez, Seunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jonathan D. Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z. Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan C. Brennick, Ryan D. Gentzler, Carrie Lee, Joleen Hubbard, Susanne M. Arnold, James L. Abbruzzese, Salma K. Jabbour, Nataliya Uboha, Kevin L. Stephans, Jennifer M. Johnson, Haeseong Park, Liza C. Villaruz, Elad Sharon, Howard Streicher, Mansoor M. Ahmed, Hayley Lyon, Carrie Cibuskis, Niall Lennon, Aashna Jhaveri, Lin Yang, Jennifer Altreuter, Lauren Gunasti, Jason L. Weirather, Raymond H. Mak, Mark M. Awad, Scott J. Rodig, Helen X. Chen, Catherine J. Wu, Arta M. Monjazeb, F. Stephen Hodi
Summary: Radiotherapy did not enhance the efficacy of combined PD-L1 plus CTLA-4 inhibition in NSCLC patients resistant to PD(L)-1 therapy. However, PD-L1 plus CTLA-4 therapy could be considered as a treatment option for certain patients.
Article
Environmental Sciences
Bethany Jablonski Horton, Nolan A. Wages, Ryan D. Gentzler
Summary: The trial uses a Bayesian design to select the optimal treatment combination of chemotherapy and immunotherapy, balancing safety and efficacy in different patient cohorts. The study aims to identify the ideal dose combination for each patient group, considering the increasing use of combination therapies in cancer treatment.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Oncology
Fatemeh Ardeshir-Larijani, Sandra K. Althouse, Ticiana Leal, Lawrence Eric Feldman, Taher Abu Hejleh, Malini Patel, Ryan D. Gentzler, Adam Ryan Miller, Nasser H. Hanna
Summary: The BTCRC-LUN 17-139 study evaluated the efficacy and safety of Atezolizumab plus Carboplatin plus Pemetrexed plus Bevacizumab in untreated advanced non-squamous non-small cell lung cancer patients. Despite a notably prolonged progression-free survival (PFS), the study did not meet the primary endpoint and the PFS result was not statistically significant compared to the historical control. The study was closed early due to three on-treatment deaths and five thromboembolic events.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Fabian J. J. Bolte, Sloane McTavish, Nathan Wakefield, Lindsey Shantzer, Caroline Hubbard, Arun Krishnaraj, Wendy Novicoff, Ryan D. D. Gentzler, Richard D. D. Hall
Summary: This study investigated the association of sarcopenia with overall survival in patients with advanced non-small cell lung cancer undergoing concurrent immune checkpoint inhibitor and chemotherapy treatment. The results showed that sarcopenia was independently associated with poor overall survival, along with other factors such as ECOG score, prognostic nutritional index, and immune-related adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lindsey B. Shantzer, Sean C. Dougherty, Fabian Bolte, John W. Melson, Daniel R. Reed, Alia C. Lynch, Ryan D. Gentzler, Wendy Novicoff, Richard D. Hall
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Cynthia X. Wei, Hirva Mamdani, Ryan Gentzler, Maitri Kalra, Susan Perkins, Sandra Althouse, Shadia I. Jalal
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Ryan D. Gentzler, Liza C. Villaruz, John C. Rhee, Bethany Horton, Joseph Mock, Michael Hanley, Kyeongmin Kim, Michelle A. Rudek, Mitch A. Phelps, Michael A. Carducci, Richard Piekarz, Kwon-Sik Park, Timothy N. Bullock, Charles M. Rudin
Summary: This study evaluated the safety of combining the HDAC inhibitor entinostat with standard of care chemotherapy and immunotherapy in patients with small cell lung cancer. The results showed that the addition of entinostat resulted in early onset and severe neutropenia and thrombocytopenia, indicating that further exploration of this combination therapy is not recommended.
Article
Oncology
Ryan D. Gentzler, Nisha A. Mohindra, Shadia Jalal, Karen L. Reckamp, Richard D. Hall, Nasser H. Hanna, Young Kwang Chae, Marianna Koczywas, Irene B. Helenowski, Jyoti D. Patel
Summary: Combination chemotherapy and immunotherapy have improved survival for advanced NSCLC patients. The study showed that when using nab-paclitaxel in combination with pembrolizumab, overall survival was improved regardless of PD-L1 status compared to chemotherapy alone.
Article
Oncology
Julio Silvestre, Tracey Gosse, Paul Read, Ryan Gentzler, Benjamin Purow, Ashok Asthagiri, Elizabeth Gaughan, Patrick M. Dillon, James M. Larner, Roger T. Anderson, Jason P. Sheehan, Camilo E. Fadul
Summary: A set of measurements were proposed to evaluate the care of patients with brain metastases, including 5 outcome and 6 process measurements. Results showed that these measurements can effectively assess the survival rate and quality of care for patients under different treatment modalities.
JCO ONCOLOGY PRACTICE
(2021)